Literature DB >> 224809

Effect of 5-iodo-5'-amino-2',5'-dideoxyuridine on varicella-zoster virus in vitro.

J P Iltis, T S Lin, W H Prusoff, F Rapp.   

Abstract

The antiviral effect of the nucleoside analog 5-iodo-5'-amino-2',5'-dideoxyuridine (AIU) was tested with three isolates of varicella-zoster virus (VZV). AIU concentrations of 10 to 800 muM (3.5 to 288 mug/ml) reduced the number of plaques produced by VZV-infected cells and cell-free VZV from approximately 30 to 95%. Smaller plaque size was also observed in the presence of AIU. AIU was less effective than arabinofuranosylthymine in reducing VZV-induced plaques since as little as 5 mug of arabinofuranosylthymine per ml completely blocked plaque formation by cell-free VZV. Toxicity assays with human diploid embryo fibroblast cells were also carried out. Drug concentrations as high as 800 muM were not toxic to human diploid embryo fibroblast cells as determined by radiolabeling of cell deoxyribonucleic acid, ribonucleic acid, and protein.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224809      PMCID: PMC352795          DOI: 10.1128/AAC.16.1.92

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  SPREAD OF ZOSTER VIRUS IN HUMAN EMBRYONIC LUNG CELLS AND THE INHIBITORY EFFECT OF LODODEOXYURIDINE.

Authors:  F RAPP; D VANDERSLICE
Journal:  Virology       Date:  1964-03       Impact factor: 3.616

2.  Comparison of the DNAs of varicella-zoster viruses isolated from clinical cases of varicella and herpes zoster.

Authors:  J P Iltis; J E Oakes; R W Hyman; F Rapp
Journal:  Virology       Date:  1977-10-15       Impact factor: 3.616

3.  5-Propyl-2'-deoxyuridine: a specific anti-herpes agent.

Authors:  E De Clercq; J Descamps; D Shugar
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

4.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  5,6-Dihydro-5-azathymidine: in vitro antiviral properties against human herpesviruses.

Authors:  H E Renis
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

6.  Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells.

Authors:  T Hackstadt; L P Mallavia
Journal:  J Virol       Date:  1978-02       Impact factor: 5.103

7.  Herpes zoster and varicella infections in children with Hodgkin's disease: an analysis of contributing factors.

Authors:  F Reboul; S S Donaldson; H S Kaplan
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

8.  Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study.

Authors:  R J Whitley; S J Soong; R Dolin; G J Galasso; L T Ch'ien; C A Alford
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

9.  Induction of deoxypyrimidine kinase activity in human embryonic lung cells infected with varicella-zoster virus.

Authors:  T Ogino; T Otsuka; M Takahashi
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

10.  Differential effect of arabinofuranosylthymine of the replication of human herpesviruses.

Authors:  R L Miller; J P Iltis; F Rapp
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

View more
  2 in total

1.  Persistent Varicella-Zoster virus infection in a human rhabdomyosarcoma cell line and recovery of a plaque variant.

Authors:  J P Iltis; J Vette; G A Castellano; D L Madden; J L Sever
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

2.  In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E De Clercq; J Descamps; M Ogata; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.